Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by argenx SE

argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
From argenx SE
Via Globe NewsWire
Tickers ARGX
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
From argenx SE
Via Globe NewsWire
Tickers ARGX
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
From argenx SE
Via Globe NewsWire
Tickers ARGX
argenx Appoints Ana Cespedes to Board of Directors
From argenx SE
Via Globe NewsWire
Tickers ARGX
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
From argenx SE
Via Globe NewsWire
Tickers ARGX
argenx Enters Into Agreement To Acquire Priority Review Voucher
From argenx SE
Via Globe NewsWire
Tickers ARGX
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
From argenx SE
Via Globe NewsWire
Tickers ARGX
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via Globe NewsWire
Tickers ARGX
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
From argenx SE
Via Globe NewsWire
Tickers ARGX
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
From argenx SE
Via Globe NewsWire
Tickers ARGX
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
From argenx SE
Via Globe NewsWire
Tickers ARGX
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via Globe NewsWire
Tickers ARGX
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
From argenx SE
Via Business Wire
Tickers ARGX
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
From argenx SE
Via Business Wire
Tickers ARGX
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
From argenx SE
Via Business Wire
Tickers ARGX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.